Skip Navigation

Annals of Oncology 2004 15(9):1310-1318; doi:10.1093/annonc/mdh342
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (15)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Zaniboni, A.
Right arrow Articles by Labianca, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zaniboni, A.
Right arrow Articles by Labianca, R.
Related Collections
Right arrow 2004 - Review Articles
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 European Society for Medical Oncology

Review

Adjuvant therapy for stage II colon cancer: an elephant in the living room?

A. Zaniboni1,* and R. Labianca2 On behalf of GISCAD (Gruppo Italiano per lo Studio e la Cura dei Tumori del Digerente)

1 Oncologia Medica, Casa di Cura Poliambulanza, Brescia; 2 Oncologia Medica, Ospedali Riuniti di Bergamo, Bergamo, Italy

* Correspondence to: Dr A. Zaniboni, Via Gabriele Rosa, 3, 25121, Brescia, Italy. Email: zanib{at}numerica.it

At present, standard adjuvant treatment for patients with stage III colon cancer after surgical resection is represented by 6 months of chemotherapy based on 5-fluorouracil/leucovorin regimens. Even elderly patients enjoy the benefit of chemotherapy in terms of superior overall survival with no detrimental effects on quality of life. More questionable is the role of adjuvant chemotherapy for stage II colon cancer patients, the standard of care for whom is surgical resection alone. Although a majority of patients will be cured with resection, a significant minority will ultimately relapse, suggesting the need to identify patients who may benefit from adjuvant therapy. Putative prognostic markers for stage II patients, as well as the state-of-the-art of the adjuvant treatment in this setting, are reviewed in this paper.

Key words: adjuvant therapy, Dukes' B stage II colon cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
A. Sezeur, F.P. Chatelet, Ch. Cywiner, Cl. de Labriolle-Vaylet, C. Chastang, Cl. Billotey, M. Malafosse, D. Gallot, P. Betton, F. Montravers, et al.
Pathology Underrates Colon Cancer Extranodal and Nodal Metastases; Ex vivo Radioimmunodetection Helps Staging
Clin. Cancer Res., September 15, 2007; 13(18): 5592s - 5597s.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
G. Galizia, E. Lieto, F. Ferraraccio, F. De Vita, P. Castellano, M. Orditura, V. Imperatore, A. La Mura, G. La Manna, M. Pinto, et al.
Prognostic Significance of Epidermal Growth Factor Receptor Expression in Colon Cancer Patients Undergoing Curative Surgery
Ann. Surg. Oncol., June 1, 2006; 13(6): 823 - 835.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
T. Andre, D. Sargent, J. Tabernero, M. O'Connell, M. Buyse, A. Sobrero, J.-L. Misset, C. Boni, and A. de Gramont
Current Issues in Adjuvant Treatment of Stage II Colon Cancer
Ann. Surg. Oncol., June 1, 2006; 13(6): 887 - 898.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Lanza, R. Gafa, A. Santini, I. Maestri, L. Guerzoni, and L. Cavazzini
Immunohistochemical Test for MLH1 and MSH2 Expression Predicts Clinical Outcome in Stage II and III Colorectal Cancer Patients
J. Clin. Oncol., May 20, 2006; 24(15): 2359 - 2367.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
C. Codignola, F. Zorzi, A. Zaniboni, S. Mutti, A. Rizzi, E. Padolecchia, and G. B. Morandi
Is there any Role for Sentinel Node Mapping in Colorectal Cancer Staging? Personal Experience and Review of the Literature
Jpn. J. Clin. Oncol., November 1, 2005; 35(11): 645 - 650.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Krajewska, H. Kim, C. Kim, H. Kang, K. Welsh, S.-i. Matsuzawa, M. Tsukamoto, R. G. Thomas, N. Assa-Munt, Z. Piao, et al.
Analysis of Apoptosis Protein Expression in Early-Stage Colorectal Cancer Suggests Opportunities for New Prognostic Biomarkers
Clin. Cancer Res., August 1, 2005; 11(15): 5451 - 5461.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.